DVYSR — Devyser Diagnostics AB Share News
0.000.00%
Last trade - 00:00- SEK844.49m
- SEK809.29m
- SEK250.50m
Brief: Devyser Wins Tender Of About SEK 3.5 Mln For Thalassemia In Italy
Brief: Devyser Q1 Sales SEK 50.7 Million
Brief: Devyser Gets IVDR Approval For Post-Transplant Monitoring Software
Brief: Devyser Diagnostics Partners With Hamilton
Brief: Devyser Gets MDSAP Certification For Brazil
Brief: Devyser Diagnostics Secures CFTR NGS Proposal With UNC Hospitals
Brief: Devyser Diagnostics Is Not Proposing Dividend For 2023
Brief: Devyser Q4 Sales SEK 45.4 Million
Brief: Devyser Genomic Laboratories Signs First Commercial Agreement
Brief: Devyser Diagnostics Wins Tender In Italy
Brief: Devyser Signs In Vitro Diagnostic Agreement With Illumina
Brief: Devyser Wins Tender For Cystic Fibrosis
Brief: Devyser Wins Tender For Non-Invasive Fetal RHD Testing In Wales
Brief: Devyser Q3 Sales SEK 46.7 Million
Brief: Devyser, Thermo Fisher Scientific Collaborate To Promote Laboratory Services To Advance Pharmaceutical Research
Brief: Devyser, Thermo Fisher Scientific Collaborate
Brief: Devyser And Thermo Fisher Scientific Expand Collaboration
Brief: Devyser Q2 Sales at SEK 37.7 Million
Brief: Devyser's NGS Products For Monitoring Of Kidney And Stem Cell Transplanted Patients Receive IVDR Approvals